Bioinformatics analysis and experimental verification of TIGD1 in non-small cell lung cancer

• Published in: Frontiers in medicine Vol. 11; p. 1374260
• Main Authors: Xia, Lingchun, Yang, Zhuofan, Xv, Mingming, Wang, Guohui, Mao, Yaxin, Yang, Yihan, Tang, Jian
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 08.04.2024
• Subjects: bioinformatics analysis; drug sensitivity; gene therapy; lung cancer; Medicine; oncology; lung cancer; gene therapy; drug sensitivity; bioinformatics analysis; oncology
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2024.1374260

Non-small cell lung cancer (NSCLC) is a prevalent respiratory system tumor. Triggered transposable element derivative 1 (TIGD1) exhibits significant overexpression in various tumor cells and tissues, suggesting its involvement in cancer progression. Clinical data and gene expression profiles of lung adenocarcinoma were collected from TCGA, UCSC XENA, and GEO databases. Computational techniques and empirical studies were employed to analyze the role of TIGD1 in NSCLC. Cellular experiments were conducted using the H1299 cell line, including RNA interference, cell viability assays, quantitative PCR, wound-healing assays, western blotting, and plate clone formation assays. Bioinformatics analysis revealed TIGD1's potential as a biomarker for diagnosing and predicting lung cancer. It also indicated promise as a target for immune-related therapy and targeted drug therapy. Cellular studies confirmed TIGD1's involvement in cancer cell proliferation, invasion, and migration. Furthermore, an association between TIGD1 and the PI3K/AKT signaling pathway was suggested. The findings suggest that TIGD1 plays a vital role in NSCLC progression, making it a potential diagnostic biomarker and therapeutic target. The association with the PI3K/AKT signaling pathway provides insights into the underlying molecular mechanisms. Integrating computational analysis with empirical studies enhances our understanding of TIGD1's significance in NSCLC and opens avenues for further research into targeted therapies.